01 August 2019
Visiongain has launched a new pharma report Global Rare Disease Drugs Market Forecast 2019-2029: Oncology, Metabolic Diseases, Neurologic Diseases, Haematology Diseases, Infectious Diseases, Specialty Pharmacies, Hospital Pharmacies, Retail Pharmacies.
The global rare disease drugs market is one that is driven by innovation which is vital for maintaining the rich pipeline of rare diseases drugs seen in the market today. There is an increasing focus to identify and treat rare diseases that currently are undertreated which creates a strong platform for both start-ups and larger pharmaceutical companies to create new drugs that are not already on the market.
The lead analyst of the report commented "It is difficult to investigate rare diseases as the pool of patients is very small and often results in inadequate clinical knowledge. As a result, rare diseases lack published data on long-term outcomes of treatment and are often characterized incompletely. This requires exploring international and regional research partnerships, collaborating with doctors working on any rare disease, and with patient groups and families dealing with the consequences of these disorders."
Leading companies featured in the report AbbVie, Bristol-Myers Squibb (BMS), Celgene, Merck & Co., Inc., Novartis, Pfizer, Roche, Sanofi, Takeda, Teva and other companies.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 20 7549 9987.
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The increasing rates of patent expiry lead to a counter-strategy of switching companies from Rx to OTC. In the US, according to the Consumer Healthcare Products Association, approximately 106 ingredients and dosage strengths have undergone a change from Rx to OTC to around 700 OTC products on the market.
23 September 2020
. The growth of this market is majorly driven by increasing sales of temperature sensitive pharmaceutical products, longer life expectancy and rising geriatric population are some of the prominent factors.
16 September 2020
Visiongain forecasts a continuing growth in global market, submarket and product sales as human vaccines drive pharmaceutical business sales. New key players and technological progress will enter the industry, leading to an increase in the market size of the world market for human vaccines in general.
14 September 2020
The global ophthalmic ultrasound systems market is driven by factors such as the increasing prevalence of ocular disorders and diseases, adoption of novel ophthalmic technologies, rising focus on research & development, and growing health awareness amongst the population.